Log In
Print
BCIQ
Print
Print this Print this
 

oral methylnaltrexone (MNTX) (Oral Relistor) (MOA-728)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionPeripheral mu opioid receptor (MOR) antagonist
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC); Treat opioid-induced constipation (OIC) in non-cancer patients with chronic pain
Regulatory Designation

Partner

Salix Pharmaceuticals Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today